

AMENDMENT

Please enter the following amendments:

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A composition for inhibiting specific gene expression with reduced side effects, the composition comprising a modified CpG-containing phosphorothioate oligonucleotide that is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, wherein the modified CpG is selected from the group consisting of alkylphosphonate CpG, ~~inverted CpG~~, 2'-O-substituted CpG, stereospecific phosphorothioate CpG, phosphotriester CpG, phosphoramidate CpG, and 2'-5' CpG.
2. (canceled).
3. (previously presented) A method for modulating gene expression in a mammal with reduced side effects comprising administering to the mammal a composition according to claim 1, wherein the oligonucleotide is complementary to a gene that is being expressed in the mammal.
4. (previously presented) A method for therapeutically treating, with reduced side effects, a disease caused by aberrant gene expression, the method comprising administering to an individual having the disease a composition according to claim 1, wherein the oligonucleotide is complementary to a gene that is aberrantly expressed, wherein such aberrant expression causes the disease.
5. (previously presented) A method for reducing side effects of a CpG-containing phosphorothioate oligonucleotide administered to a mammal, comprising:
 - (a) providing a CpG-containing phosphorothioate oligonucleotide having a CpG modification selected from the group consisting of alkylphosphonate CpG,

inverted CpG, 2'-O-substituted CpG, stereospecific phosphorothioate CpG, phosphotriester CpG, phosphoramidate CpG, and 2'-5' CpG; and

(b) administering the modified CpG-containing phosphorothioate oligonucleotide to the mammal, wherein administration of the modified CpG-containing phosphorothioate oligonucleotide results in fewer side effects than the administration of an unmodified CpG-containing phosphorothioate oligonucleotide.